FALTEJSKOVÁ, Petra, Ondřej BOČÁNEK, Milana ŠACHLOVÁ, Marek SVOBODA, Igor KISS, Rostislav VYZULA and Ondřej SLABÝ. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomarkers. Amsterdam: IOS Press, 2012, vol. 12, 4-5, p. 199-204. ISSN 1574-0153. Available from: https://dx.doi.org/10.3233/CBM-130308.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer
Authors FALTEJSKOVÁ, Petra (203 Czech Republic, belonging to the institution), Ondřej BOČÁNEK (203 Czech Republic, belonging to the institution), Milana ŠACHLOVÁ (203 Czech Republic), Marek SVOBODA (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic), Rostislav VYZULA (203 Czech Republic) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution).
Edition Cancer Biomarkers, Amsterdam, IOS Press, 2012, 1574-0153.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.972
RIV identification code RIV/00216224:14740/12:00065584
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3233/CBM-130308
UT WoS 000317228600006
Keywords in English microRNAs; serum; colorectal cancer; biomarkers
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 6/4/2014 06:18.
Abstract
BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Therefore, there is a high demand for cost-effective and non-invasive biomarkers that would enable an early detection of asymptomatic and curable disease with high sensitivity and specificity. OBJECTIVE: The main objective of this study was to investigate the potential of circulating miRNAs as biomarkers of CRC. METHODS: Total RNA enriched for small RNAs was isolated from 100~sera of patients with CRC and 30 sera of healthy donors. The expression levels of miR-17-3p, miR-29a, miR-92a and miR-135b were determined using quantitative real-time PCR. The average expression levels of particular miRNAs were normalized to miR-16 levels and statistically evaluated. RESULTS: Using Mann-Whitney U test, no significant differences were observed in miR-17-3p (P=0.18), miR-29a (P=0.14) and miR-92a (P=0.60) levels between sera of CRC patients and controls. The levels of miR-135b in serum were too low to be quantified accurately. Subsequently, we tried to correlate expression levels of analyzed miRNAs to clinical-pathological features of CRC patients. Only levels of mir-29a were correlated with the clinical stage (P=0.04). Expression levels of the other miRNAs were correlated neither with the clinical stage, nor with the grade. CONCLUSIONS: Interestingly, our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
NT13549, research and development projectName: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem
PrintDisplayed: 20/7/2024 04:17